Business
We are listed on The Nasdaq Global Market ("Nasdaq") under the symbol "EDAP." Our technologies are primarily used in urology, with a current focus on the treatment of prostate cancer.
EDAP TMS SA: Revenue grew 1.6% to $70.53M from $69.39M. Net loss widened to $29.25M from $20.58M. Operating cash flow outflow widened to $16.41M from $14.7M. Operating margin contracted 298 bps to -35.01%. EDAP TMS SA's annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 1.6% to $70.53M from $69.39MOK
- Profitability — Net loss widened to $29.25M from $20.58MWatch
- Cash flow — Operating cash flow outflow widened to $16.41M from $14.7MWatch
- Margins — Operating margin contracted 298 bps to -35.01%Watch
- Accounting — Distress-range screen needs contextWatch
- Insiders — 1 purchase and 0 salesOK
Where the revenue comes from
Fiscal 2025, as EDAP TMS SA reports it. History and quarterly detail are in the app.
- High Intensity Focused Ultrasound HIFU$37.4M
- Distribution Division$25.7M
- Lithotripsy Eswl$7.5M
Leadership changes
From EDAP TMS SA's own filings, the day they're filed.
- Stanford University Graduate School · director · appointment
- Glen French · Directors · departure
- David Horn · departure
Latest filings
- 8-K · Company announcement2026-08-19
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about EDAP TMS SA, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.